Tango Therapeutics, Inc. Total Liabilities
Tango Therapeutics, Inc. (TNGX) had Total Liabilities of $49.35 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-11
- 2026-06-30: Liabilities $49.35M.
- 2026-03-31: Liabilities $44.29M.
- 2025-12-31: Liabilities $52.51M.
- 2025-09-30: Liabilities $50.10M.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $49.35M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $44.29M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $52.51M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $50.10M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $102.94M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $107.55M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $116.97M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $123.25M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $133.78M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $141.77M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $149.46M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $151.59M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $166.38M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $176.51M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $186.99M 10-K · filed 2024-03-18 | |
| 2022-09-30 | $191.08M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $149.69M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $151.17M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $155.41M 10-K · filed 2023-03-27 | |
| 2021-09-30 | $164.72M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $6.19M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $6.14M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $168.65M 10-K · filed 2022-03-28 | $5.95M 10-K · filed 2021-03-31 |
| 2020-09-30 | $5.95M 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |